National survey of comprehensive pharmacy services provided in cancer clinical trials

2017 ◽  
Vol 74 (11_Supplement_2) ◽  
pp. S35-S41 ◽  
Author(s):  
Anand Khandoobhai ◽  
Ming Poi ◽  
Katherine Kelley ◽  
Jay Mirtallo ◽  
Ben Lopez ◽  
...  
Keyword(s):  
Clinical Trials ◽  
National Survey ◽  
Cancer Clinical Trials ◽  
Pharmacy Services

Signaling inhibition with radiation in colorectal cancer: Clinical trials

2003 ◽  
Vol 30 (3 Suppl 6) ◽  
pp. 56-67 ◽  
Author(s):  
W. Gillies McKenna ◽  
Ruth J. Muschel ◽  
Anjali Gupta ◽  
Stephen Hahn ◽  
Eric J. Bernhard
Keyword(s):  
Colorectal Cancer ◽  
Clinical Trials ◽  
Cancer Clinical Trials

scholarly journals Publication Rate and Characteristics of Lung Cancer Clinical Trials

2019 ◽  
Vol 2 (11) ◽  
pp. e1914531
Author(s):  
Ghassan Al-Shbool ◽  
Hira Latif ◽  
Saira Farid ◽  
Shuqi Wang ◽  
Jaeil Ahn ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Clinical Trials ◽  
Publication Rate ◽  
Cancer Clinical Trials

Venous thromboembolism in cancer clinical trials: recommendation for standardized reporting and analysis

2012 ◽  
Vol 10 (12) ◽  
pp. 2599-2601 ◽  
Author(s):  
M. CARRIER ◽  
A. A. KHORANA ◽  
J. I. ZWICKER ◽  
G. H. LYMAN ◽  
G. LE GAL ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Venous Thromboembolism ◽  
Cancer Clinical Trials ◽  
Standardized Reporting

scholarly journals Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade

2021 ◽  
Vol 9 (4) ◽  
pp. e002231
Author(s):  
Romain Banchereau ◽  
Avantika S. Chitre ◽  
Alexis Scherl ◽  
Thomas D. Wu ◽  
Namrata S. Patil ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Clinical Trials ◽  
Cancer Progression ◽  
Cd8 T Cells ◽  
Clonal Expansion ◽  
T Cell Response ◽  
High Dimensional ◽  
Cancer Clinical Trials ◽  
Complex Phenotype ◽  
Cytotoxic Proteins

BackgroundCD8+ tissue-resident memory T (TRM) cells, marked by CD103 (ITGAE) expression, are thought to actively suppress cancer progression, leading to the hypothesis that their presence in tumors may predict response to immunotherapy.MethodsHere, we test this by combining high-dimensional single-cell modalities with bulk tumor transcriptomics from 1868 patients enrolled in lung and bladder cancer clinical trials of atezolizumab (anti-programmed cell death ligand 1 (PD-L1)).ResultsITGAE was identified as the most significantly upregulated gene in inflamed tumors. Tumor CD103+ CD8+ TRM cells exhibited a complex phenotype defined by the expression of checkpoint regulators, cytotoxic proteins, and increased clonal expansion.ConclusionsOur analyses indeed demonstrate that the presence of CD103+ CD8+ TRM cells, quantified by tracking intratumoral CD103 expression, can predict treatment outcome, suggesting that patients who respond to PD-1/PD-L1 blockade are those who exhibit an ongoing antitumor T-cell response.

Sign in / Sign up

Export Citation Format

Share Document